Mood stabilizers
lithium and valproates are widely used in the treatment of
bipolar disorder. It has been shown that these drugs can affect the
inositol monophosphatase activity and thus the
inositol de novo biosynthesis. However, the molecular mechanism of this action has thus far been vague. As such, characterizing the regulation of the gene encoding
inositol monophosphatase at the molecular level can help to understand the
bipolar disorder. As the model organism, the
inositol monophosphatase is encoded by INM1 in Saccharomyces cerevisiae. In this study, we showed, using real-time
reverse transcriptase polymerase chain reaction analysis, that INM1 is expressed in the presence of
inositol, suggesting that the presence of
inositol is required for INM1 transcriptional activation. We also demonstrated, using
chromatin immunoprecipitation, that Ino2p is present at the promoter under uninduced conditions. Upon induction, Ino2p dissociates from the INM1 promoter. Furthermore,
chromatin remodelers Ino80p and Snf2p are recruited to INM1 promoter upon induction as well as
histone acetylases Gcn5p and Esa1p. Altogether, we have provided the evidence which describes how the transcriptional activator and coactivators participate in INM1 activation.